The potential of pathogenetic therapy in the treatment of new coronavirus infection COVID-19
https://doi.org/10.21292/2075-1230-2022-100-6-46-52
- Р Р‡.МессенРТвЂВВВВВВВВжер
- РћРТвЂВВВВВВВВнокласснРСвЂВВВВВВВВРєРСвЂВВВВВВВВ
- LiveJournal
- Telegram
- ВКонтакте
- РЎРєРѕРїРСвЂВВВВВВВВровать ссылку
Full Text:
Abstract
The objective: to increase efcacy of treatment of patients with new coronavirus infection COVID-19 by prescription of Remaxol.
Subjects and Methods: 105 patients with confrmed new coronavirus infection COVID-19 with lung damage from 25 to 50% (CT-2) were examined and divided into 2 groups (Main Group and Comparison Group). All patients received standard treatment; patients from Main Group (55 people) additionally received Remaxol intravenously 200.0 ml No. 10 daily, then No. 5 every other day. Treatment efcacy was assessed between the 3rd and 4th week of the study.
Results: the patients treated with Remaxol showed more pronounced positive changes of clinical and laboratory symptoms (lower frequency of fever, improved state of health, appetite, decreased dyspnea, cough and wheezing, higher level of SpO2, decreased neutrophilia and blood clotting, ferritin levels, a signifcant increase in activity of superoxide dismutase in erythrocytes and a decrease in myeloperoxidase activity in neutrophils) versus patients receiving standard treatment. The CT lung scan after 3 weeks in patients from Main Group showed the transformation of ground-glass areas into impactions according to the consolidation type in 58.2% (32 people), in 52.2% (29 people) there appeared an organizing pneumonia, a decrease in size of impactions was observed in 54.6% (30 people); in Comparison Group ‒ in 24.0% (12 people), 20% (10 people) and 24% (12 people), respectively, in all three comparisons (p < 0.05).
About the Authors
L. A. Shovkun
Rostov State Medical University
Russian Federation
Russian Federation
Lyudmila A. Shovkun, Doctor of Medical Sciences, Professor, Head of Tuberculosis Department
29, Nakhichevansky Lane, Rostov-on-Don, 344022
D. A. Kudlay
Immunology Research Institute; I. M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Russian Federation
Dmitry A. Kudlay, Doctor of Medical Sciences, Leading Researcher of Personalized Medicine and Molecular Immunology Laboratory no.71
24, Kashirskoye Highway, Moscow, 115522.
Phone: +7 (499) 617-10-27
E. D. Kampos
Rostov State Medical University
Russian Federation
Russian Federation
Elena D. Kampos, Candidate of Medical Sciences, Associate Professor of Tuberculosis Department
29, Nakhichevansky Lane, Rostov-on-Don, 344022
N. Yu. Nikolenko
Moscow Municipal Scientifc Practical Center of Tuberculosis Control
Russian Federation
Russian Federation
Nikolay Yu. Nikolenko, Researcher of Research Clinical Department
10, Stromynka St., Moscow, 107014.
Phone: +7 (499) 268-00-05
I. F. Shlyk
Rostov State Medical University
Russian Federation
Russian Federation
Irina F. Shlyk, Candidate of Medical Sciences, Associate Professor of
Cardiology, Rheumatology and Functional Diagnostics Department
29, Nakhichevansky Lane, Rostov-on-Don, 344022
A. M. Sarychev
Monoinfection Hospital of Zdorovye Clinical Diagnostic Center
Russian Federation
Russian Federation
Aleksey M. Sarychev, Head of Admission Department
12, Adygeyskaya St., Rostov-on-Don, 344002.
Phone: +7 (863) 210-55-22
References
1. Voronina T.A. Antioxidants/antihypoxants: the missing puzzle piece in effective pathogenetic therapy for COVID-19. Infectious Diseases (Infektsionnye Bolezni), 2020, vol. 18, no. 2, pp. 97-102. (In Russ.)
2. Vremennye metodicheskie rekomendatsii. Profilaktika, diagnostika i lechenie novoy koronavirusnoy infektsii (COVID-19) MZ RF. [Provisional guidelines on prevention, diagnostics and treatment of the new coronavirus infection (COVID-19), the Russian Ministry of Health]. Moscow, 2020.
3. Ivanova D.A., Borisov S.E., Nikolenko N.Yu. Efficacy of ademetionine in drug-induced liver injury against the background of anti-tuberculosis therapy. Tuberkulez i Sotsialno-Znachimye Zabolevaniya, 2018, no. 1, pp. 20-23. (In Russ.)
4. Ivanova D.A., Kudlay D.A., Borisov S.E., Nikolenko N.Yu. The effectiveness of silymarin in the prevention of drug-induced liver damage in patients with tuberculosis. Tuberkulez i Sotsialno-Znachimye Zabolevaniya, 2017, no. 4, pp. 28-33. (In Russ.)
5. Kovalenko A.L., Sukhanov D.S., Romantsov M.G. Efficiency of the original drug of Remaxol, solution for infusions, in liver lesions of various genesis. Farmatsevticheskaya Promyshlennost, 2010, no. 4, pp. 58-61. (In Russ.)
6. Kozlov V.A., Tikhonova E.P., Savchenko A.A., Kudryavtsev I.V., Andronova N.V., Anisimova E.N., Golovkin A.S., Demina D.V., Zdzitovetskiy D.E., Kalinina Yu.S., Kasparov E.V., Kozlov I.G., Korsunskiy I.A., Kudlay D.A., Kuzmina T. Yu., Minoranskaya N.S., Prodeus A.P., Starikova E.A., Cherdantsev D.V., Chesnokov A.B., Shesternya P.A., Borisov A.G. Klinicheskaya immunologiya: Prakticheskoye posobiye dlya infektsionistov. [Clinical immunology. A practical guide for infectious diseases specialists]. Krasnoyarsk, Polikor Publ., 2021, 563 p.
7. Lukyanova L.D. Signalnyye mekhanizmy gipoksii. Monografiya. [Signaling mechanisms of hypoxia. Monograph]. Moscow, Izd-vo RAN Publ., 2019, 214 p. ISBN978-5-907036-45-1.
8. Pinegin B.V., Vorobyova N.V., Paschenkov M.V., Chernyak B.V. The role of mitochondrial reactive oxygen species in the activation of innate immunity. Immunologiya, 2018, vol. 39, no. 4, pp. 221-229. (In Russ.)
9. Saidov M.Z., Pinegin B.V. The spectrophotometric method for the determination of myeloperoxidase in phagocytic cells. Laboratornoye Delo, 1991, no. 3, pp. 56-59. (In Russ.)
10. Sukhanov D.S., Petrov A.Yu., Kovalenko A.L., Romantsov M.G. Induction of endogenous S- adenosyl- L- methionine in hepatic cells in pharmacotherapy of toxic and drug induced liver lesions in the experiment. Eksperimentalnaya i Klinicheskaya Farmakologiya, 2011, vol. 74, no. 10, pp. 34-39. (In Russ.)
11. Fisenko V.P., Chichkova N.V. The modern COVID-19 pandemic and medications. Eksperimentalnaya i Klinicheskaya Farmakologiya, 2020, no. 4, pp. 43-44. (In Russ.)
12. Shovkun L.A., Kudlay D.A., Nikolenko N.Yu., Kampos E.D. Pulmonary tuberculosis and free-radical oxidation. Tuberkulez i Sotsialno-Znachimye Zabolevaniya, 2019, no. 2, pp. 56-61. (In Russ.)
13. Baig A. M., Khaleeq A., Ali U., Syeda H. Evidence of the COVID-19 virus targeting the CNS: tissue distribution, host-virus interaction, and proposed neurotropic mechanisms. ACS Chem. Neurosci., 2020, vol. 11, no. 7, pp. 995-998.
14. Cecchini R., Cecchini A.L. SARS-CoV-2 infection pathogenesis is related to oxidative stress as a response to aggression. Med. Hypotheses, 2020, vol. 143, pp. 110102.
15. Delgado-Roche L., Mesta F. Oxidative stress as key player in severe acute respiratory syndrome coronavirus (SARS-CoV) Infection. Arch. Med. Res., 2020, vol. 51, no. 5, pp. 384-387.
16. Matthew Z.T., Poh C.M., Renia L., MacAry P.A., Ng L.F.P. The trinity of COVID-19: immunity, inflammation and intervention. Nat. Rev. Immunol., 2020, no. 20, pp. 363-374.
17. Mehta P., McAuley D.F., Brown M., Sanchez E., Tattersall R.S., Manson J.J. et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet, 2020, vol. 395, no. 10229, pp. 1033-1034.
18. Moore J.B., June C.H. Cytokine release syndrome in severe COVID-19. Science, 2020, vol. 368, no. 6490, pp. 473-474.
19. Osman M.S., van Eeden C., Cohen T.J.W. Fatal COVID-19 infections: Is NK cell dysfunction a link with autoimmune HLH? Autoim. Rev., 2020, vol. 19, no. 7, pp. 102561.
20. Ruscitti P., Berardicurti O., Cipriani P., Iagnocco A., Shoenfeld Y. Severe COVID-19, another piece in the puzzle of the hyperferritinemic syndrome. An immunomodulatory perspective to alleviate the storm. Front. Immunol., 2020, vol. 11, pp. 1130.
21. Semenza G.L. O2-regulated gene expression: transcriptional control of cardiorespiratory physiology by HIF-1. J. Appl. Physiol., 2004, vol. 96, no. 3, pp. 1173-1172.
22. Shovkun L., Kudlay D., Nikolenko N., Kampos E. Pathogenetic treatment of patients with new coronavirus infection COVID-19. Eur. Respir. J., 2021, no. 58, suppl. 65, PA801.
23. Winterburn C.C., Havkins R.T., Bian M., Karve R.W. The estimation of cell superoxide dismutase activity. J. Lab. Clin. Med., 1975, vol. 85, no. 2, pp. 337-341.
Review
For citations:
Shovkun L.A., Kudlay D.A., Kampos E.D., Nikolenko N.Yu., Shlyk I.F., Sarychev A.M. The potential of pathogenetic therapy in the treatment of new coronavirus infection COVID-19. Tuberculosis and Lung Diseases. 2022;100(6):46-52. (In Russ.) https://doi.org/10.21292/2075-1230-2022-100-6-46-52
Views:
802
ISSN 2075-1230 (Print)
ISSN 2542-1506 (Online)
ISSN 2542-1506 (Online)
Email this article 